DOI: 10.36347/sjams.2015.v03i07.014

Pages: 2506-2512

Patients with metastatic breast cancer represent a heterogeneous group, whose prognosis and outcome may be dependent on multiple patient and tumor related factors. The objective of this retrospective study was to review demographic and clinico pathologic features and assesses treatment outcomes in primary metastatic breast cancer patients. During the period from January 2003 to December 2012, 302 patients with stage IV breast cancer at time of diagnosis treated at Clinical Oncology and Nuclear Medicine Department, Alexandria Main University Hospital were included in this analysis. Comprehensive clinico pathologic and treatment-related data were retrieved from medical records, survival outcomes were estimated and correlated to various prognostic and predictive factors. In results the median follow-up time was 16 months. The median progression free survival (PFS) after first line treatment was 10 months, while the median overall survival (OS) time was 18 months. Older age, positive hormonal receptor status and bone/soft tissue metastases only were associated with an improved survival. Whereas, menopausal status and loco regional treatment were not found to be statistically significant predictors of survival. In conclusion the general characteristics of the primary tumor are important for the prognosis and survival of patients with denovo metastatic breast cancer. These should be taken in account to achieve appropriate individualized therapeutic decisions.